Last updated on July 2019

A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy


Brief description of study

The purpose of this study is to compare the safety and efficacy of risankizumab versus placebo in subjects with moderately to severely active psoriatic arthritis (PsA).

Clinical Study Identifier: NCT03675308

Find a site near you

Start Over

Affinity Health /ID# 210816

Oak Brook, IL United States
  Connect »

OrthoIllinois /ID# 205300

Rockford, IL United States
  Connect »

Springfield Clinic /ID# 200244

Springfield, IL United States
  Connect »

June DO, PC /ID# 208915

Lansing, MI United States
  Connect »

Privia Health /ID# 207307

New York, NY United States
  Connect »

Paramount Medical Research Con /ID# 201583

Middleburg Heights, OH United States
  Connect »

Health Research Oklahoma /ID# 168027

Oklahoma City, OK United States
  Connect »

PCCR Solution /ID# 208386

Colleyville, TX United States
  Connect »

PCCR Solutions /ID# 210597

Fort Worth, TX United States
  Connect »

Hospital Italiano de Buenos Aires /ID# 208474

Ciudad Autonoma Buenos Aires, Argentina
  Connect »

DOM Centro de Reumatologia /ID# 208479

Ciudad Autonoma Buenos Aires, Argentina
  Connect »

Instituto CAICI /ID# 169168

Rosario, Santa FE, Argentina
  Connect »

Cimer /Id# 169167

San Miguel de Tucuman, Argentina
  Connect »

CGM Research Trust /ID# 210498

Burwood Christchurch, New Zealand
  Connect »

McBk Sc /Id# 209132

Grodzisk Mazowiecki, Poland
  Connect »

Yale University /ID# 207236

New Haven, CT United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.